Indian Journal of Pharmacology Home 

SHORT COMMUNICATION
[View FULLTEXT] [Download PDF]
Year : 2020  |  Volume : 52  |  Issue : 1  |  Page : 49--52

Use of rituximab in muscle-specific tyrosine kinase antibody-positive myasthenia gravis: Preliminary observations from a tertiary care center in Northern India

Julie Sachdeva, Karthik Vinay Mahesh, Ritu Shree, Gaurav Jain, Aastha Takkar Kapila, Tirulapati Padmavathi Shashikala, Manoj Kumar Goyal, Manish Modi, Vivek Lal 
 Department of Neurology, Postgraduate Institute of Medical and Research, Chandigarh, India

Correspondence Address:
Dr. Tirulapati Padmavathi Shashikala
Department of Neurology, Postgraduate Institute of Medical and Research, Chandigarh - 160 012
India

OBJECTIVES: Approximately 10%–15% of patients with myasthenia gravis (MG) are refractory to standard treatment. A sizable chunk of these patients is due to muscle-specific tyrosine kinase (MuSK) antibody-positive MG which often runs a severe course with frequent relapses and poor response to conventional treatment. We report six patients with refractory MuSK-positive MG who responded well to the treatment with rituximab. PATIENTS AND METHODS: In this prospective institute-based observational study, we report six MuSK antibody-positive MG patients, who did not achieve remission with standard treatment and were later started on rituximab infusion. RESULTS: There was a significant clinical improvement in all patients after starting rituximab. CONCLUSION: Rituximab is an effective immunomodulatory therapy in MuSK antibody-positive MG patients who are not responding to the standard treatment.


How to cite this article:
Sachdeva J, Mahesh KV, Shree R, Jain G, Kapila AT, Shashikala TP, Goyal MK, Modi M, Lal V. Use of rituximab in muscle-specific tyrosine kinase antibody-positive myasthenia gravis: Preliminary observations from a tertiary care center in Northern India.Indian J Pharmacol 2020;52:49-52


How to cite this URL:
Sachdeva J, Mahesh KV, Shree R, Jain G, Kapila AT, Shashikala TP, Goyal MK, Modi M, Lal V. Use of rituximab in muscle-specific tyrosine kinase antibody-positive myasthenia gravis: Preliminary observations from a tertiary care center in Northern India. Indian J Pharmacol [serial online] 2020 [cited 2020 Aug 3 ];52:49-52
Available from: http://www.ijp-online.com/article.asp?issn=0253-7613;year=2020;volume=52;issue=1;spage=49;epage=52;aulast=Sachdeva;type=0